| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Warren E. Zimmer | Q42722649 |
| Karen M Doersch | Q55754979 | ||
| P2093 | author name string | Kelvin A Moses | |
| P2860 | cites work | The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat | Q24648890 |
| Inflammation in prostate cancer progression and therapeutic targeting | Q26773610 | ||
| P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor β expression and enhanced matrix metalloproteinase 9 secretion | Q28281866 | ||
| Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer | Q28659468 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| CIN85 modulates TGFβ signaling by promoting the presentation of TGFβ receptors on the cell surface | Q30009137 | ||
| Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy | Q33370145 | ||
| Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer | Q33470429 | ||
| T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer | Q33952036 | ||
| Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis | Q34107357 | ||
| The role of interleukin-2 during homeostasis and activation of the immune system | Q34255232 | ||
| TGFβ signaling plays a critical role in promoting alternative macrophage activation | Q34306291 | ||
| Overexpression of Transforming Growth Factor β1 in Malignant Prostate Cells is Partly Caused by a Runaway of TGF-β1 Auto-induction Mediated Through a Defective Recruitment of Protein Phosphatase 2A by TGF-β Type I Receptor | Q34384729 | ||
| Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer | Q34432723 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells. | Q34563034 | ||
| Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer | Q34563201 | ||
| Guideline for the management of clinically localized prostate cancer: 2007 update. | Q34629234 | ||
| LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems | Q34700552 | ||
| CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells | Q34709777 | ||
| Prostate cancer as a model for tumour immunotherapy | Q34856875 | ||
| P21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition | Q35235907 | ||
| Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer. | Q35388139 | ||
| Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen | Q35581016 | ||
| ELL Protein-associated Factor 2 (EAF2) Inhibits Transforming Growth Factor β Signaling through a Direct Interaction with Smad3 | Q35775160 | ||
| Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer | Q35806990 | ||
| Association between tumor-associated macrophages and microvessel density on prostate cancer progression. | Q35809905 | ||
| Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages | Q35831305 | ||
| ShcA Protects against Epithelial-Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation | Q35872442 | ||
| TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion | Q35883901 | ||
| TG-4010 Transgene | Q36008445 | ||
| A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. | Q36288241 | ||
| Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth | Q36351780 | ||
| Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. | Q36498243 | ||
| Autophagy is required for IL-2-mediated fibroblast growth | Q36585665 | ||
| APPL proteins promote TGFβ-induced nuclear transport of the TGFβ type I receptor intracellular domain | Q36729386 | ||
| Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. | Q36946516 | ||
| Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy | Q37193043 | ||
| TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. | Q37244144 | ||
| Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy | Q37680355 | ||
| Interleukin-2 toxicity | Q37776348 | ||
| Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer | Q38407369 | ||
| Transforming growth factor-β signaling induced during prostate cancer cell death and neuroendocrine differentiation is mediated by bone marrow stromal cells | Q38833670 | ||
| Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells | Q38874906 | ||
| The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer | Q39036208 | ||
| Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression | Q39144790 | ||
| STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion | Q39159528 | ||
| Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma | Q39487932 | ||
| A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity | Q39550599 | ||
| IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation | Q39673752 | ||
| Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial | Q39814025 | ||
| Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist | Q40048436 | ||
| Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial | Q40130124 | ||
| TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial | Q40149008 | ||
| CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients | Q40212457 | ||
| Early IL-2 Production by Mouse Dendritic Cells Is the Result of Microbial-Induced Priming | Q40649514 | ||
| Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial | Q40794891 | ||
| Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. | Q40874708 | ||
| TGF Beta1 Expression Correlates with Survival and Tumor Aggressiveness of Prostate Cancer | Q41485074 | ||
| Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor-beta | Q41741733 | ||
| Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. | Q41825885 | ||
| Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site | Q41854472 | ||
| Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing | Q41953761 | ||
| Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization | Q41967899 | ||
| The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy | Q42391707 | ||
| Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer | Q42432955 | ||
| Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity | Q42451248 | ||
| The gamma subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon gamma, and transforming growth factor beta 1. | Q42501588 | ||
| Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction | Q42768300 | ||
| Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model | Q43407443 | ||
| The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate | Q44324752 | ||
| Rapamycin unbalances the polarization of human macrophages to M1. | Q45057583 | ||
| miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer | Q45877197 | ||
| Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology | Q45877652 | ||
| Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. | Q46648813 | ||
| Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. | Q47726082 | ||
| Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. | Q50720226 | ||
| MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu. | Q54317518 | ||
| Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2 | Q60193080 | ||
| Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice. | Q64978760 | ||
| Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness | Q69880388 | ||
| Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2 | Q71542471 | ||
| The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells | Q71602232 | ||
| Differences in the expression and effects of interleukin-1 and -2 on androgen-sensitive and -insensitive human prostate cancer cell lines | Q73594067 | ||
| Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells | Q77929206 | ||
| IL-2 gene C/T polymorphism is associated with prostate cancer | Q79371145 | ||
| MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure | Q79642618 | ||
| P433 | issue | 17 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1900-1910 | |
| P577 | publication date | 2016-07-20 | |
| P1433 | published in | Experimental Biology and Medicine | Q15716535 |
| P1476 | title | Synergistic immunologic targets for the treatment of prostate cancer | |
| P478 | volume | 241 |
| Q96131453 | A QSP model of prostate cancer immunotherapy to identify effective combination therapies |
| Q89531807 | Blood platelets stimulate cancer extravasation through TGFβ-mediated downregulation of PRH/HHEX |
| Q99579001 | Immunotherapy in prostate cancer: current state and future perspectives |
| Q39093352 | Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. |
| Q41478244 | Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer |
Search more.